TM
VRDN icon

Torren Management’s Viridian Therapeutics VRDN Stock Holding History

Torren Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$386 Hold
21
– – ﹤0.01% 883
2026
Q1 		$411 Hold
21
– – ﹤0.01% 905
2025
Q4 		$654 Buy
+21
New +$576 ﹤0.01% 1289

Other funds holding VRDN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Torren Management's VRDN Position: Q2 2026 in Review

Torren Management held its Viridian Therapeutics (VRDN) position steady in Q2 2026 at 21 shares worth $386. The position accounts for ﹤0.01% of the portfolio, ranked #883.

Torren Management first reported a position in VRDN in Q4 2025 and has held it in 3 quarters since. The position peaked at $654 in Q4 2025. 65 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Torren Management held 21 shares of Viridian Therapeutics worth $386 as of Q2 2026.
  • Torren Management left its Viridian Therapeutics share count unchanged in Q2 2026.
  • Viridian Therapeutics made up ﹤0.01% of Torren Management's portfolio in Q2 2026, its #883 holding.
  • Torren Management first reported a position in Viridian Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Torren Management's Viridian Therapeutics position peaked at $654 in Q4 2025.
  • 65 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Torren Management's 13F filing for Q2 2026, filed 10 Jul 2026.